Iantrek key facts
as of Oct 2026- Developer of a minimally invasive technology designed to offer ophthalmic medical devices.
- Iantrek is valued at approximately $95.0M as of Oct 2026, set at its later-stage round, Aug 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $73.0M across 4 recorded rounds; the latest was Early Stage VC ($34.7M) in Aug 2025.
- Notable investors include FemHealth Ventures, Civilization Ventures, JSD Capital, Sectoral Asset Management, U.S. Venture Partners — 7 tracked in total.
- Iantrek has filed 4 Form Ds with the SEC since 2020, most recently Aug 2025 ($34.7M sold to 21 investors).
- Status: Privately Held (backing).
Valued at $95.0M at its later-stage round, Aug 2025. Nothing has traded since.
- ·Watch Iantrek: the Monday email on marks, rounds and moves
Iantrek funding rounds
4 roundsIantrek valuation
Iantrek was valued at $95 million at its later-stage round in Aug 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Iantrek raised?
Iantrek has raised $73 million across 4 recorded rounds since 2020. The largest was a $5.2 million early-stage round in Oct 2020; the most recent was a $34.7 million early-stage round in Aug 2025.
Iantrek has filed 4 Form Ds with the SEC since 2020, most recently in Aug 2025 ($34.7 million sold to 21 investors).
Iantrek investors
7 investors are on record for Iantrek, including FemHealth Ventures, Civilization Ventures, JSD Capital and Sectoral Asset Management. The early-stage round in Aug 2025 drew 21 investors.
About Iantrek
Developer of a minimally invasive technology designed to offer ophthalmic medical devices. The company offers advanced micro-interventional surgical technologies, enabling doctors to help in eye surgery with smaller incisions and shorter recovery times.
- Sector
- Healthcare
- HQ
- White Plains, NY, United States
- Founded
- 2019
- Employees
- 49
- Website
- iantrekmed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.